IL6 and asthma: That is, most patients developed eosinophilic inflammation, which our previous work indicated was unlikely to be attenuated by TCZ.8 Because of funding constraints, it was not feasible in our trial to selectively recruit patients with mixed‐granulocytic sputum after allergen challenge, but this should be considered in future studies of IL‐6 signalling inhibitors in asthma.